Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 10:58 PM ET

Pharmaceuticals

Company Overview of Acetylon Pharmaceuticals, Inc.

Company Overview

Acetylon Pharmaceuticals, Inc. discovers and develops selective small molecule histone deacetylase inhibitors and other targeted drugs for the treatment of cancers, inflammatory, neurodegenerative, genetic, and infectious diseases. It has a strategic partnership with Celgene Corporation. The company was founded in 2008 and is based in Boston, Massachusetts.

70 Fargo Street

Suite 205

Boston, MA 02210

United States

Founded in 2008

Phone:

617-245-1300

Fax:

617-245-1301

Key Executives for Acetylon Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 58
Co-Founder and Chairman of the Board
Age: 52
Scientific Founder, Director and Member of the Advisory Board
Age: 42
Scientific Founder and Member of the Advisory Board
Scientific Founder, Director and Member of the Advisory Board
Age: 64
Compensation as of Fiscal Year 2015.

Acetylon Pharmaceuticals, Inc. Key Developments

The Hereditary Neuropathy Foundation Announces New Partnership with Acetylon Pharmaceuticals, Inc. to Explore Potential Therapies for Charcot-Marie-Tooth Disease

The Hereditary Neuropathy Foundation (HNF) announced a new partnership with Acetylon Pharmaceuticals, Inc. As a supplement to HNF’s long-standing collaboration with University of Sheffield, Acetylon will provide an HDAC6 inhibitor compound for testing in a preclinical model of Charcot-Marie-Tooth (CMT), the most common inherited peripheral neuropathy. To date, HNF has committed $1.5 million to CMT research as part of their Therapeutic Research In Accelerated Discovery (TRIAD) program, which fosters collaboration among academics, government and industry to accelerate potential treatments for CMT. In addition to the Acetylon partnership, HNF will continue to approve expenditures to expedite the search for treatments and cures.

Acetylon Pharmaceuticals, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 01:30 PM

Acetylon Pharmaceuticals, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 01:30 PM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Walter C. Ogier, Chief Executive Officer, President and Director.

Acetylon Pharmaceuticals Announces Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma

Acetylon Pharmaceuticals, Inc. announced results from three Phase 1b clinical trials of the selective HDAC6 inhibitor, ricolinostat (ACY-1215), in different single-agent and combination regimens for the treatment of lymphoma and multiple myeloma. The safety and tolerability of ricolinostat (ACY-1215) was investigated in an open-label, single agent, multi-institutional Phase 1b clinical trial in patients with relapsed or refractory lymphoid malignancies. The study was conducted by investigators from the Columbia University Medical Center, New York, NY. The target population for enrollment included patients with histologically confirmed relapsed or refractory non-Hodgkin’s lymphoma or Hodgkin’s lymphoma, with an expansion cohort of patients with mantle cell lymphoma. Ricolinostat was well tolerated in these patients, dosed daily (QD) or twice daily (BID), with no dose-limiting toxicities. The most common adverse events were diarrhea, nausea, and pain, which were all low grade. Ricolinostat also demonstrated promising clinical activity in monotherapy with 37% of patients achieving stable disease on a 160 mg BID dose schedule. The promising clinical activity and favorable tolerability seen in this study support further exploration in Phase 2 studies. The Phase 1b ACY-100 clinical trial was designed to determine the optimal dose of ricolinostat (ACY-1215) in combination with bortezomib (Velcade®, Millennium) and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma. Dosing data from this study indicate that a dose of 160 mg QD, in combination with intravenous or subcutaneous administration of bortezomib, is well tolerated. In the 18 patients receiving ricolinostat at 160 or 240 mg QD, an overall response rate (defined as partial response or better) of 33% was achieved, with many having durable responses of 6 months or more. In the 32 patients who were refractory to bortezomib, 69% had stable disease or better and 13% responded, including one very good partial response. The Phase 1b ACE-MM-101 clinical trial was an open-label, multicenter study designed to determine the optimal dose of ricolinostat in combination with lenalidomide (Revlimid®, Celgene) and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma. In the study, ricolinostat was well tolerated in combination with lenalidomide and dexamethasone over a range of doses and schedules. The most common treatment emergent adverse events (AEs) were fatigue, diarrhea and hematologic toxicity, and most were low grade; no maximum tolerated dose was identified. A dose of 160 mg QD on days 1-21 of a 28-day cycle was chosen as the optimal Phase 2 dose based on the occurrence of dose-limiting toxicities in the two BID cohorts and similar observations of more favorable tolerability with once daily dosing in other ricolinostat combination studies. There were 38 patients that were evaluable for response and an overall response rate (defined as partial response or better) of 55% was achieved. An overall response rate of 25% was achieved in the 12 patients that were refractory to lenalidomide. Patients who responded to treatment were on study for a median duration of 12 months, with some patients continuing up to 33 months. Nine patients remain on study.

Similar Private Companies By Industry

Company Name Region
Celtaxsys, Inc. United States
Azaya Therapeutics Incorporated United States
Gliacure, Inc. United States
GeneriCo LLC United States
EI, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Acetylon Pharmaceuticals, Inc., please visit www.acetylon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.